


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Date Submitted: October 21, 2003

(use as many sheets as necessary)

1

of

1

**Complete if Known**

Application Number	10/691,905
Filing Date	July 15, 2003
First Named Inventor	Karim Boumediene
Group Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	065691-0327

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
MG	A1	U.S. 6,146,616		Msika	11-14-2000	
	A2	U.S. 5,998,396		Nakano	12-07-1999	
↓	A3	U.S. 5,627,289		Jeromin	05-06-1997	
	A4	U.S. 5,498,411		Rancurel	03-12-1996	
MG	A5	U.S. 5,262,163		Rancurel	11-16-1993	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
MG	A6	FR	2 231 394			12-27-1974		
	A7	EP	0 643 960			03-22-1995		
↓	A8	FR	2 762 512			10-30-1998		
	A9	FR	2 678 632			01-08-1993		
↓	A10	GB	1 427 253			03-10-1976		
MG	A11	CA	2132369			03-22-1995		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
MG	A12	International Search Report for PCT/FR99/03272 (WO 00/38701)	
	A13	Helen Kim et al., "Mechanisms of Action of the Soy Isoflavone Genistein: Emerging Role for its Effects Via Transforming Growth Factor-β Signaling Pathways 1-3", The American Journal of Clinical Nutrition, vol. 68, No. 6, (suppl), pgs. 1418S-1425S, (1998) © 1998 American Society for Clinical Nutrition.	
↓	A14	Par H. Thiers et al., "Un Groupe D'Agents Therapeutiques Noveaux: Les Insaponifiables Des Huiles Vegetables, Leurs Carotenoids, Leurs Indetermines Administres En Solution Alcoolique", Therapie, vol 16, pgs. 235-251, 1961	
MG	A15	Pharmascience Laboratories "PIASCLEDINE 300 mg gelules," 1992, previously available at <a href="http://www2.biam2.org/www/spe11021.html">http://www2.biam2.org/www/spe11021.html</a>	
*	A16	VIDAL, "PIASCLLEDINE 900 mg gel", available at <a href="http://www.vidal.fr/medicament/piasclledine-13107.htm">http://www.vidal.fr/medicament/piasclledine-13107.htm</a>	

Examiner Signature	/Michel Graffeo/	Date Considered	12/29/2006
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

No date available for this publication.

001.1456318.1